Skip to main content
    6

    60 Degrees Pharmaceuticals, Inc. Common Stock (SXTP)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.49
    -0.02 (-4.60%)

    Market Cap: $1.82M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    60 Degrees Pharmaceuticals, Inc. Common Stock (SXTP) Financials: Revenue, Profit and Cash Flow

    Updated Nov 12, 2026. Financial statements from company filings, amounts in US dollars.

    60 Degrees Pharmaceuticals, Inc. Common Stock reported revenue of $1.41M for the fiscal year ended Dec 31, 2025, up 106.8% from the year before. That year, net income was -$7.37M with a net margin of -522.9%, operating cash flow was -$6.85M and free cash flow was -$6.99M. The quarter ended Sep 30, 2026 had revenue of $233.24K and net income of -$2.56M.

    Revenue and Margins

    Over the 5 years to Dec 2025, revenue fell from $2.18M, a compound annual decline of 8.3%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$1.41M+106.8%44.5%-550.6%-522.9%
    Dec 2024$681.35K+168.7%43.5%-1425.9%-1167.6%
    Dec 2023$253.57K-50.4%-87.1%-2032.8%-1504.0%
    Dec 2022$511.21K-55.9%-40.9%-342.4%-1208.5%
    Dec 2021$1.16M-46.8%26.7%-96.9%-366.4%
    Dec 2020$2.18MN/A67.8%-19.2%-139.1%
    Annual, fiscal years ended Dec 2020 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
    Revenue$1.41M$681.35K$253.57K$511.21K$1.16M$2.18M
    Cost of revenue$781.70K$384.76K$474.55K$432.37K$850.74K$702.99K
    Gross profit$627.40K$296.58K-$220.98K-$209.16K$309.60K$1.48M
    Research and development$2.11M$4.99M$691.77K$525.56K$5.51M$806.68K
    Operating income-$7.76M-$9.72M-$5.15M-$1.75M-$1.12M-$418.13K
    Net income-$7.37M-$7.96M-$3.81M-$6.18M-$4.25M-$3.03M
    EBITDA-$7.10M-$4.31M-$3.44M-$1.06M-$1.01M-$341.17K
    Fiscal years ended Dec 2020 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$233.24K$207.90K$162.09K$409.11K$528.56K$307.87K$256.28K$302.59K$148.11K$124.97K$105.67K$118.27K
    Gross profit-$97.53K$56.80K$76.38K$586.33K-$100.09K$50.88K$90.28K$197.33K$23.61K$35.41K$40.24K-$20.58K
    Operating income-$2.53M-$2.27M-$2.09M-$1.92M-$2.33M-$1.61M-$1.91M-$2.07M-$2.12M-$4.19M-$1.34M-$1.89M
    Net income-$2.56M-$2.27M-$2.09M-$1.44M-$2.32M-$1.73M-$1.88M-$2.48M-$2.16M-$4.17M$858.46K-$6.23M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded total debt of $152.78K by $1.36M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
    Total assets$5.37M$5.76M$7.78M$1.30M$1.39M$2.61M
    Current assets$4.90M$5.39M$7.24M$1.10M$1.18M$2.44M
    Cash and equivalents$1.51M$1.66M$2.14M$264.87K$115.40K$191.70K
    Total liabilities$1.99M$1.80M$2.99M$25.45M$19.55M$20.68M
    Short-term debt$8.77K$8.77K$22.42K$21.33M$140.68K$53.31K
    Long-term debt$144.00K$147.12K$150.25K$1.11M$18.74M$15.92M
    Shareholder equity$3.46M$4.04M$4.87M-$23.58M-$17.58M-$17.50M
    Fiscal years ended Dec 2020 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$3.09M$4.28M$6.76M$5.37M$6.69M$4.18M$5.98M$5.76M$7.42M$4.33M$8.38M$7.78M
    Total liabilities$2.34M$1.75M$2.02M$1.99M$2.34M$1.84M$1.95M$1.80M$1.46M$1.37M$1.25M$2.99M
    Cash and equivalents$306.19K$1.02M$3.34M$1.51M$4.12M$1.97M$3.45M$1.66M$3.30M$1.58M$2.89M$2.14M
    Shareholder equity$842.02K$2.61M$4.83M$3.46M$4.43M$2.43M$4.11M$4.04M$6.04M$3.04M$7.20M$4.87M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
    Operating cash flow-$6.85M-$5.65M-$4.54M-$1.01M-$649.11K-$167.30K
    Capital expenditures$139.88K$103.77K$57.62K$33.06K$35.39K$70.98K
    Free cash flow-$6.99M-$5.75M-$4.60M-$1.04M-$684.50K-$238.28K
    Share repurchasesN/AN/AN/A$68.63KN/AN/A
    Investing cash flow$254.92K-$1.89M-$115.89K-$60.13K-$35.39K-$70.98K
    Financing cash flow$6.44M$7.05M$6.47M$1.22M$611.23K$277.36K
    Fiscal years ended Dec 2020 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$1.45M-$2.23M-$2.74M-$1.69M-$2.11M-$1.45M-$1.60M-$1.64M-$1.68M-$1.19M-$1.14M-$63.67K
    Capital expendituresN/AN/A$30.00K$79.88K$10.00K$47.32K$2.68K$2.10K$13.77K$90.00K$0$55.80K
    Free cash flowN/AN/A-$2.77M-$1.77M-$2.12M-$1.50M-$1.60M-$1.64M-$1.69M-$1.28M-$1.14M-$119.47K
    Last 12 quarters

    Frequently Asked Questions About SXTP

    What is 60 Degrees Pharmaceuticals, Inc. Common Stock's annual revenue?

    60 Degrees Pharmaceuticals, Inc. Common Stock reported revenue of $1.41M for the fiscal year ended Dec 31, 2025.

    How fast is 60 Degrees Pharmaceuticals, Inc. Common Stock's revenue growing?

    Revenue was up 106.8% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 40.2%.

    Is 60 Degrees Pharmaceuticals, Inc. Common Stock profitable?

    No. 60 Degrees Pharmaceuticals, Inc. Common Stock reported net income of -$7.37M for the fiscal year ended Dec 31, 2025, with a net margin of -522.9%.

    How much free cash flow does SXTP generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$6.85M minus capital expenditures of $139.88K produced free cash flow of -$6.99M.

    How much debt does 60 Degrees Pharmaceuticals, Inc. Common Stock have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $144.00K, short-term debt of $8.77K and cash and equivalents of $1.51M.